article thumbnail

Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials

VirTrial

In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.

article thumbnail

Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials

VirTrial

In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials

VirTrial

In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.

article thumbnail

Subjective Measures, Objective Outcomes: Data Quality in Atopic Dermatitis Clinical Trials

VirTrial

In recent years, there has been significant activity in the AD clinical trial landscape, including the approval of novel systemic therapies. Accurate measurement of AD severity over time is crucial for evaluating treatment efficacy in these trials. JAMA Dermatology , 149 (5), 577-582. References: Armstrong, A.

article thumbnail

June 26, 2024: Using ChatGPT to Facilitate Informed Medical Consent, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

Mirza is chief resident in the Department of Dermatology at the Warren Alpert Medical School of Brown University. The post June 26, 2024: Using ChatGPT to Facilitate Informed Medical Consent, in This Week’s PCT Grand Rounds appeared first on Rethinking Clinical Trials. Join the online meeting.

article thumbnail

Digital clinical trials: Trends to watch in 2023

Pharmaceutical Technology

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

article thumbnail

LEO partners with ICON to offer patient-centric dermatology trials

Drug Discovery World

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.